EZH2 as a new therapeutic target in brain tumors: Molecular landscape, therapeutic targeting and future prospects

Basit Öğe Kaydı
dc.authoridAli Zarrabi / 0000-0003-0391-1769en_US
dc.authorscopusidAli Zarrabi / 23483174100
dc.authorwosidAli Zarrabi / U-2602-2019
dc.contributor.authorPaskeh, Mahshid Deldar Abad
dc.contributor.authorMehrabi, Atefeh
dc.contributor.authorGholami, Mohammad Hossein
dc.contributor.authorZabolian, Amirhossein
dc.contributor.authorRanjbar, Ehsan
dc.contributor.authorZarrabi, Ali
dc.date.accessioned2021-12-21T06:05:50Z
dc.date.available2021-12-21T06:05:50Z
dc.date.issued2022en_US
dc.departmentİstinye Üniversitesi, Mühendislik ve Doğa Bilimleri Fakültesi, Biyomedikal Mühendisliği Bölümüen_US
dc.description.abstractBrain tumors are responsible for high mortality and morbidity worldwide. The brain tumor treatment depends on identification of molecular pathways involved in progression and malignancy. Enhancer of zeste homolog 2 (EZH2) has obtained much attention in recent years in field of cancer therapy due to its aberrant expression and capacity in modulating expression of genes by binding to their promoter and affecting methylation status. The present review focuses on EZH2 signaling in brain tumors including glioma, glioblastoma, astrocytoma, ependymomas, medulloblastoma and brain rhabdoid tumors. EZH2 signaling mainly participates in increasing proliferation and invasion of cancer cells. However, in medulloblastoma, EZH2 demonstrates tumor-suppressor activity. Furthermore, EZH2 can regulate response of brain tumors to chemotherapy and radiotherapy. Various molecular pathways can function as upstream mediators of EZH2 in brain tumors including lncRNAs and miRNAs. Owing to its enzymatic activity, EZH2 can bind to promoter of target genes to induce methylation and affects their expression. EZH2 can be considered as an independent prognostic factor in brain tumors that its upregulation provides undesirable prognosis. Both anti-tumor agents and gene therapies such as siRNA have been developed for targeting EZH2 in cancer therapy.en_US
dc.identifier.citationPaskeh, M., Mehrabi, A., Gholami, M. H., Zabolian, A., Ranjbar, E., Saleki, H., Ranjbar, A., Hashemi, M., Ertas, Y. N., Hushmandi, K., Mirzaei, S., Ashrafizadeh, M., Zarrabi, A., & Samarghandian, S. (2021). EZH2 as a new therapeutic target in brain tumors: Molecular landscape, therapeutic targeting and future prospects. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 146, 112532. Advance online publication.en_US
dc.identifier.doi10.1016/j.biopha.2021.112532en_US
dc.identifier.pmid34906772en_US
dc.identifier.scopus2-s2.0-85120949351en_US
dc.identifier.scopusqualityN/Aen_US
dc.identifier.urihttps://doi.org/10.1016/j.biopha.2021.112532
dc.identifier.urihttps://hdl.handle.net/20.500.12713/2332
dc.identifier.volume146en_US
dc.identifier.wosWOS:000732990700004en_US
dc.identifier.wosqualityQ1en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.institutionauthorZarrabi, Ali
dc.language.isoenen_US
dc.publisherElsevieren_US
dc.relation.ispartofBiomedicine & Pharmacotherapyen_US
dc.relation.publicationcategoryDiğeren_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectBiomarkeren_US
dc.subjectDrug Resistanceen_US
dc.subjectEZH2 Inhibitorsen_US
dc.subjectEnhancer of Zeste Homolog 2 (EZH2)en_US
dc.subjectNon-coding RNAs.en_US
dc.titleEZH2 as a new therapeutic target in brain tumors: Molecular landscape, therapeutic targeting and future prospectsen_US
dc.typeReview Articleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
41.pdf
Boyut:
3.66 MB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

PubMed İndeksli Yayınlar Koleksiyonu
Biyomedikal Mühendisliği Bölümü Makale Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu